Perrigo Company Acquisitions and Exits, 31 Deals Between 2001 and 2017
life science Company

Perrigo Company has acquired 26 companies, including 6 in the last 5 years. A total of 2 acquisitions came from private equity firms. It has also divested 5 assets.

Perrigo Company’s largest acquisition to date was in 2013, when it acquired Elan for $8.6B. It’s largest disclosed sale occurred in 2017, when it sold TYSABRI to Royalty Pharma for $2.9B. Perrigo Company has acquired in 12 different US states, and 9 countries. The Company’s most targeted sectors include medical products (39%) and consumer products (20%).

Join Mergr and gain access to Perrigo Company’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

Perrigo Company PLC

Treasury Building, Lower Grand Canal Street,
Dublin, 2
Ireland,
+353 1 604 0031
www.perrigo.com

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo was formed in 1887 and is based in Dublin, Ireland.

M&A Summary

Buy vs Sell

Year ≤ '14 '15 '16 '17 '18 '19 T
Buy (0.8/yr) # 22 2 2 - - - 26
vol $15.8B $15.8B
Sell (1.0/yr) # - - 1 4 - - 5
vol $2.9B $2.9B
  31

Top M&A Advisors

Financial Deals
Sign-up to View
3
Sign-up to View
1
Sign-up to View
1
Legal Deals
Sign-up to View
4
Sign-up to View
1
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Elan Corp. plc
$8.6B (2013-12-18)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest TYSABRI (natalizumab)
$2.9B (2017-02-27)

Life Science M&A - Last 3 Years

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 403 life science companies that have made at least 1 acquisition, 13 have acquired at least 5 companies, and 2 have acquired more than 10 companies.

The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is The Carlyle Group with 5 platform acquisitions.


What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.5K Private Equity Firms
  • 125K M&A Transactions
  • 134K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.9K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.